Sumiya Sharmin Mou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sumiya Sharmin Mou has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Fatema- Tuz- Zohora
University of Asia Pacific
2 shared publications - Abdul Muhit
Department of Clinical Pharmacy and Pharmacology University of Dhaka Dhaka Bangladesh
1 shared publication - Adeeba Jaheen Faruqui1 shared publication
- Akash Kumar Bhawmick
Department of Botany, Jagannath University, Sadarghat, Dhaka, Bangladesh
1 shared publication - Bytul Mokaddesur Rahman
Department of Pharmacy, Faculty of Science, University of Rajshahi, Rajshahi-6205, Bangladesh
1 shared publication Elias Al-Mamun
Department of Pharmaceutical Technology University of Dhaka Bangladesh
1 shared publication
Latest Publications
- Open Access
- 31 March 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 18 (1) , 939-946
Antioxidant, Cytotoxic, and Antimicrobial Activities of Pterocarpus santalinus Leaves
This study evaluates the chemical and biological properties of Pterocarpus santalinus leaf methanolic extract to establish its scientific basis for potential therapeutic applications. The phytochemical analysis revealed the presence of 595.04 mg/g flavonoids (quercetin equivalent) and 69 mg/g phenolic compounds (gallic acid equivalent), underscoring its antioxidant potential. The extract exhibited DPPH radical scavenging activity with an IC50 of 337.79 µg/ml, indicating moderate antioxidant capacity. Additionally, mild antimicrobial activity was observed against Escherichia coli and Aspergillus niger. The cytotoxic effects of the extract were assessed in HeLa cells, demonstrating a concentration-dependent relationship. At concentrations of 100 µg/ml and 200 µg/ml, cell viability remained above 95%, indicating non-toxic effects. However, at 500 µg/ml, a significant decrease in cell viability to 20-30% was observed, with an LC50 value of 365.77 µg/ml, indicating substantial cytotoxicity at higher concentrations. These results suggest that while lower concentrations are safe, higher doses may induce cell death, necessitating the establishment of safe dosage ranges for therapeutic applications. The findings support the pharmacological potential of P. santalinus leaf extract, highlighting its relevance in antioxidant, antimicrobial, and anticancer research, and warrant further investigation to refine its medicinal applications.
- 31 March 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 18 (1) , 939-946
Open AccessAntioxidant, Cytotoxic, and Antimicrobial Activities of Pterocarpus santalinus Leaves
This study evaluates the chemical and biological properties of Pterocarpus santalinus leaf methanolic extract to establish its scientific basis for potential therapeutic applications. The phytochemical analysis revealed the presence of 595.04 mg/g flavonoids (quercetin equivalent) and 69 mg/g phenolic compounds (gallic acid equivalent), underscoring its antioxidant potential. The extract exhibited DPPH radical scavenging activity with an IC50 of 337.79 µg/ml, indicating moderate antioxidant capacity. Additionally, mild antimicrobial activity was observed against Escherichia coli and Aspergillus niger. The cytotoxic effects of the extract were assessed in HeLa cells, demonstrating a concentration-dependent relationship. At concentrations of 100 µg/ml and 200 µg/ml, cell viability remained above 95%, indicating non-toxic effects. However, at 500 µg/ml, a significant decrease in cell viability to 20-30% was observed, with an LC50 value of 365.77 µg/ml, indicating substantial cytotoxicity at higher concentrations. These results suggest that while lower concentrations are safe, higher doses may induce cell death, necessitating the establishment of safe dosage ranges for therapeutic applications. The findings support the pharmacological potential of P. santalinus leaf extract, highlighting its relevance in antioxidant, antimicrobial, and anticancer research, and warrant further investigation to refine its medicinal applications.
- Open Access
- 1 January 2025
- Published by MedCrave Group Kft. in MOJ Public Health
- Vol. 14 (1) , 45-50
A longitudinal study reflecting a pandemic-driven revolution of telemedicine in Bangladesh with promising prospects
COVID-19 has been a public health crisis for quite a long time worldwide. Providing primary health care during this has proven to be quite difficult. Telemedicine played an imperative part in this by minimizing virus spread and utilizing the time of healthcare experts. This survey was designed to know about the prevalence of telemedicine during Covid-19 pandemic as well as its future prospect in Bangladesh. Four stakeholders were categorized for the study: common people, physicians, pharmaceutical professionals and regulatory body. Data was collected both via online and offline. Among the general people, 50.23% took health services through telemedicine service during the pandemic and 24.64% before the pandemic. Both general people (78.88%) and physicians (60%) expressed their satisfaction regarding the service. 93% pharmaceutical professionals also suggested that telemedicine should be implemented in all hospitals. Among the service takers 100% people were prescribed cold medicines. 58% of the respiratory issues were addressed through telemedicine. Physicians as well as regulatory authority considered raising awareness about telemedicine to be an important factor. Therefore, telemedicine should be utilized in several ways in our health sector. The post-Covid-19 era presents a unique opportunity for Bangladesh to harness the potential of telemedicine in addressing healthcare disparities and improving access to quality care. While challenges persist, strategic investments, technological innovation, and policy support can ensure that telemedicine becomes a cornerstone of a more equitable and efficient healthcare system in Bangladesh.
- 1 January 2025
- Published by MedCrave Group Kft. in MOJ Public Health
- Vol. 14 (1) , 45-50
Open AccessA longitudinal study reflecting a pandemic-driven revolution of telemedicine in Bangladesh with promising prospects
COVID-19 has been a public health crisis for quite a long time worldwide. Providing primary health care during this has proven to be quite difficult. Telemedicine played an imperative part in this by minimizing virus spread and utilizing the time of healthcare experts. This survey was designed to know about the prevalence of telemedicine during Covid-19 pandemic as well as its future prospect in Bangladesh. Four stakeholders were categorized for the study: common people, physicians, pharmaceutical professionals and regulatory body. Data was collected both via online and offline. Among the general people, 50.23% took health services through telemedicine service during the pandemic and 24.64% before the pandemic. Both general people (78.88%) and physicians (60%) expressed their satisfaction regarding the service. 93% pharmaceutical professionals also suggested that telemedicine should be implemented in all hospitals. Among the service takers 100% people were prescribed cold medicines. 58% of the respiratory issues were addressed through telemedicine. Physicians as well as regulatory authority considered raising awareness about telemedicine to be an important factor. Therefore, telemedicine should be utilized in several ways in our health sector. The post-Covid-19 era presents a unique opportunity for Bangladesh to harness the potential of telemedicine in addressing healthcare disparities and improving access to quality care. While challenges persist, strategic investments, technological innovation, and policy support can ensure that telemedicine becomes a cornerstone of a more equitable and efficient healthcare system in Bangladesh.
- Open Access
- 1 January 2024
- Published by MedCrave Group Kft. in Pharmacy & Pharmacology International Journal
- Vol. 12 (6) , 223-228
In-vitro assessment of quality control specifications for ketorolac tromethamine tablets marketed in Bangladesh
This study aims to evaluate the quality parameters of the immediate release Ketorolac tromethamine (KT) 10 mg tablet of different local brands available in Bangladesh. The evaluation was done in compliance to various Pharmacopeial quality parameters, i.e., weight variation, friability, hardness, thickness, disintegration, potency, and dissolution. Six formulations of KT were prepared by direct compression method using different super disintegrants. Micrometric properties of the mixtures of the drug and the excipients prepared for formulation were evaluated. Quality evaluation of the six different formulations and randomly selected six different brands of KT 10-mg tablets purchased from the local market were performed according to Pharmacopoeia. The results were obtained by UV-Vis spectrophotometer and all the dissolution profiles were characterized by the zero order kinetics. All the brands of KT and developed formulations met the official specification with some fluctuations in the range. The marketed ketorolac tablet's potency ranged from 93% to 97% and formulated tablets is 91.15%. The values obtained from the tests were used to analyze the degree of conformance of commercially available drugs to the USP specification that represents the quality of both commercially available and formulated tablets. All the parameters comply with the USP specifications which ensure the safe usage of ketorolac tablets in Bangladeshi population that doesn’t compromise with the quality.
- 1 January 2024
- Published by MedCrave Group Kft. in Pharmacy & Pharmacology International Journal
- Vol. 12 (6) , 223-228
Open AccessIn-vitro assessment of quality control specifications for ketorolac tromethamine tablets marketed in Bangladesh
This study aims to evaluate the quality parameters of the immediate release Ketorolac tromethamine (KT) 10 mg tablet of different local brands available in Bangladesh. The evaluation was done in compliance to various Pharmacopeial quality parameters, i.e., weight variation, friability, hardness, thickness, disintegration, potency, and dissolution. Six formulations of KT were prepared by direct compression method using different super disintegrants. Micrometric properties of the mixtures of the drug and the excipients prepared for formulation were evaluated. Quality evaluation of the six different formulations and randomly selected six different brands of KT 10-mg tablets purchased from the local market were performed according to Pharmacopoeia. The results were obtained by UV-Vis spectrophotometer and all the dissolution profiles were characterized by the zero order kinetics. All the brands of KT and developed formulations met the official specification with some fluctuations in the range. The marketed ketorolac tablet's potency ranged from 93% to 97% and formulated tablets is 91.15%. The values obtained from the tests were used to analyze the degree of conformance of commercially available drugs to the USP specification that represents the quality of both commercially available and formulated tablets. All the parameters comply with the USP specifications which ensure the safe usage of ketorolac tablets in Bangladeshi population that doesn’t compromise with the quality.